Meteora Capital’s Orchestra BioMed OBIO Stock Holding History

Meteora Capital’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-60,572	Closed	-$603K	–	410
2022 Q2	$603K	Buy	+60,572	New	+$602K	0.11%	147

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Meteora Capital's OBIO Position: Q3 2022 in Review

Meteora Capital sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 60,572 shares — an estimated $603K sold.

Meteora Capital first reported a position in OBIO in Q2 2022 and held it in 1 quarter. The position peaked at $603K in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

Meteora Capital reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
Meteora Capital sold 60,572 Orchestra BioMed shares in Q3 2022, an estimated $603K.
Meteora Capital first reported a position in Orchestra BioMed in Q2 2022 and held it in 1 quarter.
Meteora Capital's Orchestra BioMed position peaked at $603K in Q2 2022.
23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Meteora Capital's 13F filing for Q3 2022, filed 14 Nov 2022.